EP Biocomposites BSE SME IPO review (Avoid)

Review By Dilip Davda on August 24, 2022

•    EPBL is engaged in manufacturing and supplying FRP products and sanitation solutions.
•    It has marked steady growth in its top and bottom lines. 
•    Tiny equity capital post IPO indicates longer gestation for migration.
•    Based on FY22 earnings, the issue is priced aggressively.
•    There is no harm in ignoring this pricy bet. 

EP Biocomposites Ltd. (EPBL) is into manufacturing and supply of fiber reinforced polymers (FRP) products such as door shutters, frames, Biodigestor Tanks, Bio toilets, and allied products for construction and Industrial applications that meet customer requirements. The Company got into the high potential sector of wastewater recycling in 2021. The company has taken over the running business of its promoter

EPBL focuses on giving sanitation solutions to those who do not have access to toilets and those who have toilets but face trouble treating and managing the waste through septic tanks. The company provides sanitation infrastructure and human waste management solutions and services, involving innovative and simple bio-digester technology licensed from the Defence Research and Development Organization (DRDO) and Industry Interface and Technology Management, operating under the aegis of DRDO, Ministry of Defence, Government of India. 

The anaerobic bio-digester technology helps users manage waste onsite, without depending on expensive and energy-consuming sewage infrastructure. The Sewage Treatment Plant enables contaminant concentrations to be lowered to a safe level before wastewater can be reused or returned to the environment. The effluent water treatment - is a technique used for processing industrial wastewater for reuse or safe discharge to the environment. The company also specializes in FRP allied products. FRP is an eco-friendly substitute for wood that has long been the chosen building
material - a limited resource that has resulted in major environmental problems, such as fast forest decline.

The group has supplied more than 2, 00,000 doors thereby saving thousands of trees, and has supplied more than 2,500 Bio toilets to households helping in the reduction of open defecation thereby contributing to clean and green surroundings. As of March 31, 2022, it had 30 employees on its payroll.

To part finance its needs for a long-term lease deposit for a manufacturing facility (Rs. 2.00 cr.), part repayment of loans (Rs. 0.80 cr.), working capital (Rs. 1.51 cr.), and general corporate purposes (Rs. 1.49 cr.), EPBL is coming out with a maiden IPO of 504000 equity shares of Rs. 10 each at a fixed price of Rs. 126 per share to mobilize Rs. 6.35 cr. The issue opens for subscription on August 29, 2022, and will close on September 05, 2022. Minimum application is to be made for 1000 shares and in multiples thereon, thereafter. Post allotment, shares will be listed on BSE SME. The issue constitutes 30.02% of the post-issue paid-up capital of the company. EPBL is spending Rs. 0.55 cr. for this IPO process. 

The issue is solely lead managed by Aryaman Financial Services Ltd. and Bigshare Services Pvt. Ltd. is the registrar to the issue. Aryaman Group company Aryaman Capital Markets Ltd. is the market maker for this company. 

Having issued entire equity at par so far, the company also issued bonus shares in the ratio of 13 shares for every 2 shares held in September 2021. The average cost of acquisition of shares by the promoters is Rs. 7.24 and Rs. 7.88 per share. 

Post issue, EPBL's current paid-up equity capital of Rs. 1.18 cr. will stand enhanced to Rs. 1.68 cr. Based on the IPO pricing, the company is looking for a market cap of Rs. 21.19 cr. 

On the financial performance front, for the last three fiscals, EPBL has reported turnover/net profits of Rs. 0.57 cr. / Rs. 0.03 cr. (FY20), Rs. 2.95 cr. / Rs. 0.36 cr. (FY21) and Rs. 8.08 cr. / Rs. 0.81 cr. (FY22).

For the last three fiscals, EPBL has posted an average EPS of Rs. 7.17 and an average RoNW of 69.55%. The issue is priced at a P/BV of 7.42 based on its NAV of Rs. 16.97 as of March 31, 2022, and at a P/BV of 2.54 based on its post-IPO NAV of Rs. 49.65 per share.   

If we attribute FY22 earnings to post IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 26.20. Thus the issue is aggressively priced. 

The company has not declared any dividend since its inception. It will adopt a prudent dividend policy post listing, based on its financial performance and prospects. 

As per offer documents, EPBL has no listed peers to compare with. Aryaman Financial brought one IPO called Banka Bioloo Ltd. in February 2018, which could have been the nearest peer for EPBL.

This is the 14TH mandate from Aryaman Financial in the last three fiscals (including the ongoing one). Out of the last 10 listings, all opened with premiums ranging from 0.02% to 5% on the day of listing. Thus it has an average track record. 

Conclusion / Investment Strategy

Though the company has posted steady growth in its top and bottom lines, its tiny post-IPO paid-up equity capital indicates longer gestation for migration to the mainboard. Based on FY22 earnings, its IPO is priced aggressively. This pricy issue may be skipped.

Reviewer recommends Avoid to the issue.

Review By Dilip Davda on August 24, 2022

Review Author

DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. My reviews do not cover GMP market and operators game plans. Readers must consult a qualified financial advisor before making any actual investment decisions, based the on information published here. With entry barriers, SEBI wants only well-informed investors to participate in such offers. With crazy listings in the recent past, SME IPOs drew the attention of investors across the board and lead to seer madness. However, as SME issues have entry barriers and continued low preference from the broking community, any reader taking decisions based on any information published here does so entirely at their own risk. The above information is based on information available as of date coupled with market perceptions. The Author has no plans to invest in this offer.

About Dilip Davda

Dilip Davda

Dilip Davda is veteran journalist associated with stock market since 1978. He is contributing to print and electronic media on stock markets/insurance/finance since 1985.

Dilip Davda is a leading reviewer of public issues and NCDs in the primary stock market in India. The knowledge he gained over 3 decades while working in the stock market and a strong relationship with popular lead managers makes his reviews unique. His detail fundamental and financial analysis of companies coming up with IPO helps investors in the primary stock market. Dilip Davda has a special interest in analyzing the SME companies and writing reviews about their public issues. His reviews are regularly published online and in news papers.

(Dilip Davda -SEBI registered Research Analyst-Mumbai,

Registration no. INH000003127 (Perpetual)

Email id: dilip_davda@rediffmail.com ).

EP Biocomposites IPO FAQs

  1. 1. Why EP Biocomposites IPO?

    The initial public offer (IPO) of EP Biocomposites Limited offers an early investment opportunity in EP Biocomposites Limited. A stock market investor can buy EP Biocomposites IPO shares by applying in IPO before EP Biocomposites Limited shares get listed at the stock exchanges. An investor could invest in EP Biocomposites IPO for short term listing gain or a long term.

  2. 2. How is EP Biocomposites IPO?

    Read the EP Biocomposites IPO recommendations by the leading analyst and leading stock brokers.

  3. 3. EP Biocomposites IPO what should investors do?

    EP Biocomposites IPO offers an opportunity to buy IPO shares before they get listed at the stock exchanges. Read the EP Biocomposites IPO Notes, Analysis and Recommendations by leading stock brokerage firms and experts in the above answer.

  4. 4. Is EP Biocomposites IPO good?

    Our recommendation for EP Biocomposites IPO is to avoid.

  5. 5. Is EP Biocomposites IPO worth Investing?

    As per the analysis by our lead analyst Mr. Dilip Davda, we suggest you to avoid the EP Biocomposites IPO.

  6. 6. When will EP Biocomposites IPO allotment status?

    The EP Biocomposites IPO allotment status will be available on or around September 8, 2022. The allotted shares will be credited in demat account by September 12, 2022. Visit EP Biocomposites IPO allotment status to check.

  7. 7. When will EP Biocomposites IPO list?

    The EP Biocomposites IPO will list on Tuesday, September 13, 2022, at BSE SME.